PRK and LASIK reduces retinal image quality

Article

Performing photorefractive keratectomy (PRK) and laser in situ keratomileusis (LASIK) reduces the retinal image quality in myopic patients.

Performing photorefractive keratectomy (PRK) and laser in situ keratomileusis (LASIK) reduces the retinal image quality in myopic patients, declared a paper in the Journal of Cataract and Refractive Surgery.

The comparative case series, headed by Dr Meritxell Vilaseca, Universitat Politècnica de Catalunya, Terrassa, Barcelona Institute of Ocular Microsurgery, Barcelona, Spain, assessed 34 myopic eyes that underwent PRK and 55 myopic eyes that underwent LASIK.

Preoperatively and 3 months after PRK or LASIK optical quality was assessed with a clinical double-pass system. The team calculated the modulation transfer function (MTF), retinal image quality parameters (MTF cut-off frequency, Strehl ratio), and intraocular scattering [objective scatter index (OSI)].

PRK and LASIK demonstrated a statistically significant reduction on retinal image quality. However, there were no differences in reduction between the two techniques.

In the PRK group the MTF decreased by a factor of 1.50 and in the LASIK group it decreased by 1.32. The Strehl ratio was decreased by 1.10 and 1.07 for the PRK and LASIK group, respectively.

PRK and LASIK caused an increase in the objective scatter index by factors of 1.48 and 1.57, respectively. The preoperative refraction and the OSI were strongly linked.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.